OncologyTube Professional - Patients Click Here

158,392 video views
Loading........
Description: Dr. Khorana M.D., Professor of Medicine, Cleveland Clinic Lerner College of Medicine, CaseWestern Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical ...
01:06
Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018
by:ASHReport | 2 views
02:11
Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes at ASH 2018. Background Allogeneic hematopoietic cell transplantation (HCT) remain...
by:ASHReport | 3 views
01:13
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the next steps for Ixazomib in Multiple Myeloma after the results of the TOURMALINE-MM3 phase 3 trial. Key findings, which will be presented by Dr. Meletios Dimopoulos, include: The trial achieved its primary endpoint wi...
by:ASHReport | 12 views
01:06
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses Duration of Maintenance and the Advantage to High Risk Patients of the TOURMALINE-MM3 phase 3 study. Key findings, which will be presented by Dr. Meletios Dimopoulos, include: The trial achieved its primary endpoint with...
by:ASHReport | 13 views
02:09
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the results of the phase 3 study TOURMALINE-MM3. The study is the first and only Phase 3 placebo-control​led study evaluating a proteasome inhibitor (PI) in the maintenance setting to produce data. Key findings, which will be...
by:ASHReport | 10 views
02:03
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Risk Of Developing (t-MDS) After Chemo & Radiation At The 60th ASH Annual Meeting on Dec 1, 2018.
by:ASHReport | 21 views
01:48
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Reasoning Behind ALL As Second Cancer Studyy At The 60th ASH Annual Meeting on Dec 1, 2018.
by:ASHReport | 8 views
01:48
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Next Step In Research For (t-MDS) At The 60th ASH Annual Meeting on Dec 1, 2018.
by:ASHReport | 16 views
02:43
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses ALL As Second Cancer After Treatment, Explorative Study At The 60th ASH Annual Meeting on Dec 1, 2018.
by:ASHReport | 12 views
01:54
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses (t-MDS) Research & Outcomes At The 60th ASH Annual Meeting on Dec 1, 2018.
by:ASHReport | 19 views

About ASHReport


Links
Channel Url: